BMJ

The global burden of low back pain: estimates from the Global Burden of Disease 2010 study

7 Genetics and Population Health Division, Queensland Institute of Medical Research, Brsibane, Queensland, Australia 8 School of Population Health, University of Queensland, Herston, Queensland, ...
BMJ

AB1456 BIOLOGICS AND JAK INHIBITORS EFFICACY IN VEXAS SYNDROME FROM FRENCH MULTICENTER CASE SERIES OF 256 PATIENTS

Background A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome. Objectives To describe clinical characteristics, laboratory findings ...
BMJ

The global burden of neck pain: estimates from the Global Burden of Disease 2010 study

2 Department of Rheumatology, University of Sydney Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia 3 Department of Rheumatology, Royal ...
BMJ

Steroid injection for inferior heel pain: a randomised controlled trial

3 Centre for Public Health, Queens’ University Belfast, Belfast, UK 4 Department of Rheumatology, Altnagelvin Area Hospital, Londonderry, UK 5 Department of Rheumatology, Chapel Allerton Hospital, ...
BMJ

Dose-related patterns of glucocorticoid-induced side effects

Objective: To identify patterns of self-reported health problems relating to dose and duration of glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice. Methods: ...
BMJ

The global burden attributable to low bone mineral density

2 Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Departament de Reumatologia, L'Hospitalet de Llobregat, Barcelona, Spain 3 Institute for Health Metrics and ...
BMJ

The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study

Objective To estimate the global burden of hip and knee osteoarthritis (OA) as part of the Global Burden of Disease 2010 study and to explore how the burden of hip and knee OA compares with other ...
BMJ

OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED ...

Background Telitacicept (TACI-Fc fusion protein) is a novel BLyS (B-lymphocyte stimulator)/APRIL (a proliferation-inducing ligand) dual inhibitor, which has been approved in 2021 in China for the ...
BMJ

OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS

1 Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen-Nürnberg and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany 2 Deutsches Zentrum ...
BMJ

Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages

UPRES EA 1124- Ecole de Santé Publique, Faculté de Médecine, Nancy, France Professor F Guillemin, Ecole de Santé Publique, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, F 54500 Vandoeuvre ...
BMJ

The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study

1 Northern Clinical School, Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia 2 Department of Rheumatology, Royal North Shore Hospital, St Leonards, ...
BMJ

A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis

Objective We evaluate the efficacy of human umbilical cord-derived mesenchymal stem cell (hUC-MSC) for the treatment of lupus nephritis (LN). Previous reports showed hUC-MSC could have dramatic ...